Contents of this article
The musculoskeletal system, which includes bones, muscles, tendons, ligaments, and cartilage, depends on peptides for growth, repair, and signaling. Peptides act as hormones, local messengers, and therapeutic agents that regulate bone density, muscle mass, cartilage health, and tissue recovery. In recent years, peptide-based drugs have transformed the treatment of osteoporosis, muscular disorders, and joint degeneration, highlighting their role in both physiology and modern medicine.
Peptides in musculoskeletal physiology
The musculoskeletal system is dynamic, constantly balancing tissue formation, breakdown, and repair. Peptides are central to these processes, functioning as growth factors, hormones, and signaling molecules that influence bone remodeling, muscle protein synthesis, and joint health.
Bone remodeling
Bone is a living tissue continuously remodeled by osteoblasts (formation) and osteoclasts (resorption). Parathyroid hormone (PTH) is a key peptide in this cycle. When given intermittently, PTH stimulates osteoblast activity, improving bone mineral density. Other peptides, such as calcitonin, which inhibits bone resorption, and osteocalcin, which may regulate skeletal and metabolic interactions, play supporting roles in maintaining bone health.
Muscle growth and repair
Peptides regulate muscle protein synthesis and repair following exercise or injury. Insulin-like growth factor 1 (IGF-1), produced both in muscle and liver, activates satellite cells and drives hypertrophy and regeneration. Other anabolic peptide classes, including growth hormone releasing peptide (GHRP) analogs, have been explored experimentally but remain less clinically validated.
Cartilage and connective tissue
Joint cartilage, tendons, and ligaments also rely on peptide signaling. Collagen-derived peptides are widely studied for their ability to stimulate chondrocytes and improve extracellular matrix integrity. Clinical results are mixed: some trials show reductions in joint pain and improved mobility, while others find modest or no structural benefit.
Peptide therapeutics in bone disorders
PTH analogs
Two well-established peptide drugs, teriparatide (PTH 1-34) and abaloparatide, mimic PTH activity and stimulate new bone formation. Randomized controlled trials confirm significant reductions in both vertebral and non-vertebral fractures among patients with severe osteoporosis. These agents are typically prescribed for a maximum of two years, followed by antiresorptive therapy to maintain gains.
Calcitonin
While less commonly prescribed today, calcitonin peptides act directly on osteoclasts to reduce bone resorption. They are less effective than PTH analogs for fracture prevention but may provide short-term pain relief after acute vertebral fractures.
Muscle health and regenerative Peptides
IGF-1 and muscle growth
IGF-1 is central to muscle physiology, driving protein synthesis, repair, and satellite cell activation. Its direct therapeutic use is limited due to concerns about safety and cancer risk, but its pathways remain active research targets for sarcopenia and cachexia.
Experimental myostatin inhibitors
Myostatin is a peptide that naturally restricts muscle growth. Inhibiting myostatin with peptides or antibody-based biologics has been tested for muscular dystrophies and age-related muscle loss. Clinical trials demonstrate increased lean mass, though functional improvements in strength and endurance remain inconsistent.
Peptides in joint and tendon health
Collagen Peptides
Oral supplementation with collagen peptides has gained attention in athletes and older adults. Clinical studies report improvements in joint pain, stiffness, and functional mobility, although structural cartilage regeneration is not consistently observed.
BPC-157
BPC-157, a synthetic gastric pentadecapeptide, has demonstrated remarkable healing properties in preclinical models. Animal studies show accelerated tendon, ligament, cartilage, and bone repair. However, human trials remain sparse, and BPC-157 is not approved for clinical use, limiting its current application.
Advances in Peptide delivery for the musculoskeletal system
Delivering peptides effectively is a challenge due to rapid enzymatic breakdown and short half-lives. Modern solutions include:
- Depot injections (teriparatide, abaloparatide) for sustained dosing.
- Oral collagen peptides, absorbed as bioactive fragments without degradation concerns.
- Novel delivery systems, including nanoparticles, liposomal carriers, and hydrogel implants, designed to target bone or muscle tissue.
Safety and clinical considerations
Peptide therapies are generally safe but require specific considerations:
- PTH analogs: can cause transient hypercalcemia and are limited to two years of treatment.
- Collagen peptides: well tolerated but variable in clinical effect.
- Experimental agents: such as myostatin inhibitors and BPC-157, still require validation for long-term safety and efficacy.
Access and cost remain barriers, particularly for advanced drugs, underscoring the importance of more affordable formulations and equitable healthcare access.
The next generation of musculoskeletal peptide therapies is likely to focus on:
- Multi-functional peptides that act simultaneously on bone and muscle.
- Personalized peptide regimens, matched to genetic and metabolic profiles.
- Regenerative medicine approaches, combining peptides with stem cells or biomaterials.
- Oral and implantable delivery systems to improve accessibility and adherence.
Peptides are no longer just physiological signals; they are becoming precise therapies capable of preventing fractures, restoring muscle mass, and supporting joint repair. With continued advances in clinical research, peptides may soon become cornerstone tools in combating osteoporosis, sarcopenia, arthritis, and connective tissue injuries.
Research sources:
Parathyroid hormone receptor agonists in the management of osteoporosis
Nicholas Fuggle, René Rizzoli, Charlotte Beaudart, Bernard Cortet, Elizabeth M. Curtis, Mickaël Hiligsmann, Jean-Marc Kaufman, Nicola Veronese, Ben Hur Albergaria, Nasser Al-Daghri, Majed Alokail, Maria Luisa Brandi, Olivier Bruyère, Nansa Burlet, Claudia Campusano, Enrique Casado, Etienne Cavalier, Manju Chandran, Cyrus Cooper, Patrizia D’Amelio, Bess Dawson-Hughes, Peter R. Ebeling, John A. Kanis, Andreas Kurth, Radmila Matijevic, Eugene McCloskey, Michael McClung, Ouafa Mkinsi, Ngozi Njeze, Régis P. Radermecker, François Rannou, Stuart Silverman, Şansın Tüzün, Leith Zakraoui, Jean-Yves Reginster and Nicholas C. Harvey. Published in Nature reviews Rheumatology in 2025 | DOI: 10.1038/s41584-025-01287-w
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C. Harvey, Nicholas R. Fuggle, Olivier Bruyère, René Rizzoli and Jean-Yves Reginster. Published in Springer Nature Osteoporosis International 2025 | DOI: 10.1007/s00198-025-07440-1
Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy
Tadashi Yoshida and Patrice Delafontaine. Published in Cells 2020 | DOI: 10.3390/cells9091970
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies